PDS Biotech to Participate at the B. Riley Securities 3rd Annual Oncology Conference

Rhea-AI Summary

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy firm, announced participation in the B. Riley Securities 3rd Annual Oncology Conference, set for January 18-19, 2023. A fireside chat with management will occur on January 19, 2023, at 1:00 PM EST, accessible via livestream. PDS Biotech focuses on developing targeted immunotherapies for cancer and infectious diseases using its proprietary Versamune^® and Infectimune™ platforms, showing promise in clinical trials for HPV-expressing cancers.

FLORHAM PARK, N.J., Jan. 13, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that its management will participate in a fireside chat at the B. Riley Securities 3rd Annual Oncology Conference being held virtually on January 18-19, 2023.

B. Riley Securities 3rd Annual Oncology Conference
Fireside Chat: Thursday, January 19, 2023
Time: 1:00 PM EST
Virtual viewers: Livestream

About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on our proprietary Versamune^® and Infectimune™ T cell-activating technology platforms. We believe our targeted Versamune^® based candidates have the potential to overcome the limitations of current immunotherapy by inducing large quantities of high-quality, potent polyfunctional tumor specific CD4+ helper and CD8+ killer T cells. To date, our lead Versamune^® clinical candidate, PDS0101, has demonstrated the potential to reduce tumors and stabilize disease in combination with approved and investigational therapeutics in patients with a broad range of HPV-expressing cancers in multiple Phase 2 clinical trials. Our Infectimune™ based vaccines have also demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T cell responses, including long-lasting memory T cell responses in pre-clinical studies to date. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

Versamune^® is a registered trademark and Infectimune™ is a trademark of PDS Biotechnology.

Investor Contacts:
Deanne Randolph
PDS Biotech
Phone: +1 (908) 517-3613
drandolph@pdsbiotech.com

Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
pdsb@cg.capital  

Media Contacts: 
Tiberend Strategic Advisors, Inc.
Dave Schemelia 
Phone: +1 (609) 468-9325 
dschemelia@tiberend.com  

Bill Borden 
Phone: +1 (732) 910-1620 
bborden@tiberend.com

FAQ

When is PDSB's fireside chat at the B. Riley Securities Oncology Conference?

The fireside chat for PDS Biotechnology Corporation will take place on January 19, 2023, at 1:00 PM EST.

What is the focus of PDS Biotechnology Corporation?

PDS Biotechnology focuses on developing targeted immunotherapies for cancer and infectious diseases using its proprietary technology platforms.

Where can I watch PDSB's fireside chat?

The fireside chat can be viewed via a livestream on the B. Riley Securities website.

What technology does PDSB utilize for its cancer treatments?

PDSB utilizes its proprietary Versamune^® and Infectimune™ technology platforms for developing its immunotherapy treatments.

What is the significance of PDS0101 for PDSB?

PDS0101 is PDSB's lead clinical candidate, demonstrating potential to reduce tumors and stabilize disease in patients with HPV-expressing cancers.